Nectar Lifesciences


Community Pharm PCL
Concise Prescribing Info
Cefuroxime axetil
Mild to moderate infections, pharyngitis or tonsilitis; acute bacterial otitis media; acute bacterial maxilliary sinusitis; acute bacterial exacerbations of chronic bronchitis & secondary bacterial infection of acute bronchitis; uncomplicated skin & skin-structure infections; uncomplicated UTI; uncomplicated gonorrhea, urethral & endocervical; early lyme disease.
Dosage/Direction for Use
Adult & adolescents ≥13 yr Pharyngitis/tonsilitis; acute bacterial maxillary sinusitis 250 mg bid for 10 days. Acute bacterial exacerbations of chronic bronchitis; uncomplicated skin & skin-structure infections 250 or 500 mg bid for 10 days. Secondary bacterial infections of acute bronchitis 250 or 500 mg bid for 5-10 days. Uncomplicated UTI 250 mg bid for 7-10 days. Uncomplicated gonorrhea 1,000 mg as a single dose. Early lyme disease 500 mg bid for 20 days. Ped patients Acute otitis media; acute bacterial maxillary sinusitis 250 mg bid for 10 days.
May be taken with or without food.
Hypersensitivity to cephalosporins.
Special Precautions
Hypersensitivity to cefuroxime axetil, other cephalosporins or penicillins & other β-lactams. Prolonged use. Concurrent treatment w/ potent diuretics. History of colitis; GI malabsorption. Pseudomembranous colitis. May decrease prothrombin activity. Renal or hepatic impairment. Patients w/ poor nutritional state, receiving a protracted course of antimicrobial therapy & previously stabilized on anticoagulant therapy. Pregnancy & lactation.
Adverse Reactions
Diarrhea, nausea, vomiting & abdominal pain. Elevated AST, transient elevation in ALT, alkaline phosphatase & LDH; decreased in Hb & hematocrit; elevation of eosinophilia, abdominal cramps, flatulence, indigestion, headache, vaginitis; vulvar itch, rash, hives, itch, dysuria, chills, chest pain, shortness of breath, mouth ulcers, swollen tongue, sleepiness, thirst, anorexia.
Drug Interactions
Increased serum conc w/ probenecid. Lower bioavailability w/ drugs that reduce gastric acidity. Increased risk of nephrotoxicity w/ aminoglycosides. Increased renal adverse effects w/ diuretics. Reduced plasma conc w/ H2-antagonists.
MIMS Class
ATC Classification
J01DC02 - cefuroxime ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.
Neurox-250 film-coated tab
1 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in